3-13:
The control preparation of normal saline should be spelled out in the abstract. Additionally the Phase Ib, single blinded placebo controlled nature of the trial should also be spelled out. 3-29: The additional limitation of normal saline as technically (patients cannot blinded with NS compared to stool) and physiologically (auto-transplant is arguably a much better physiologic control/placebo) questionable control should be highlighted. 4-5: Significant underestimation of UC in North America. Recent epidemiology estimated 3.1 million IBD patients just in the US, close to 50% of whom had UC diagnosis in medical record. 4-8: "profound" growth impairment seems to be an overstatement for pediatric UC, without any reference to support it. 4-20: FMT is a consensus abbreviation for Fecal Microbiota Transplantation, not "fecal microbial transplant". This should be corrected and from here on only the abbreviation of FMT used throughout the manuscript. The authors randomly switch between FMT and spelling out the abbreviation throughout the paper. 4-37: Of note, patient of reference 14 had colectomy within 1 year after the publication of the case (personal communication with authors). Also discuss: Failure of Fecal Microbiota Transplantation in a Three-Year-Old Child with Severe Refractory Ulcerative Colitis. Kumagai H, Yokoyama K, Imagawa T, Inoue S, Tulyeu J, Tanaka M, Yamagata T. Pediatr Gastroenterol Hepatol Nutr. 2016 Sep; 19(3) :214-220. 4-49: Incorrect statement: Patients in reference 11 received standardized anonymous donor stool preparations, and more FMT than planned in the protocol of this paper. 4-57: An overstatement, where reference 20 gave a p=0.04 with inappropriate placebo (water enema cannot be blinded compared to stool), whereas: Rossen NG, Fuentes S, van der Spek MJ, Tijssen 
GENERAL COMMENTS
Pai N and Popov J present a protocol for a randomized, placebo controlled pilot study for assessing feasibility and efficacy of fecal microbiota transplantation (FMT) in a pediatric ulcerative colitis (UC) population: PediFetCh Trial.
Methods follow a prior protocol of FMT, which had been successfully performed in adult UC patients.
Major comments:
1. Eligibility criteria include "signs of disease activity" defined as a PUCAI score > 10. As a PUCAI score of < 10 already defines clinical remission, PUCAI score values for clinical activity have to be clearly separated from remission criteria. Following prior studies of pediatric UC and FMT (Kunde s. et al in 2013) or anti-TNF antibody therapy (Volonaki E et al. 2015) , PUCAI score for clinical activity should be at least 15.
2. The enema product of the placebo group contains polyethylene glycol (PEG) preservative and saline. PEG has a laxative effect and applied twice weekly might increase PUCAI score. To ensure equal conditions in the placebo group, the same amount of PEG should also be used preparing the product of the FMT group.
Minor comments:
1. In the rational section the authors refer to a 67-100% clinical response. In fact the cited paper of Kellermayer et al. demonstrated the prolongation of a symptom free interval due to FMT in patients after withdrawal of immunotherapy. These patients presented already with a Mayo score of 0 and 1 respectively even before the first FMT had been performed.
The cited case report of Vendaplas Y et al in 2015 deals
with serial FMT infusion in a 18month old UC patient but donors were not anonymous as written in the protocol by Pai N and Popov J but age related relatives.
Nylund L et al (BMC Microbiology 2013
) demonstrated an association of a diverse and adult-type microbiota in early childhood with eczema; this raises the question, if donors for the younger patients should be matched for age to prevent possible side effects.
VERSION 1 -AUTHOR RESPONSE
 3-13: The control preparation of normal saline should be spelled out in the abstract. Additionally, the Phase Ib, single blinded placebo controlled nature of the trial should also be spelled out.
Response to reviewer"s comment: Addressed.
 4-5: Significant underestimation of UC in North America. Recent epidemiology estimated 3.1 million IBD patients just in the US, close to 50% of whom had UC diagnosis in medical record.
 4-8: "profound" growth impairment seems to be an overstatement for pediatric UC, without any reference to support it. Response to reviewer"s comment: Addressed: "A diagnosis of ulcerative colitis can be debilitating in childhood.  7-6: Age limits for eligibility should be clearly stated (i.e. maximum age). FDA/NIH uses 16y for drug trials. Show age criteria in Figure 1 as well.
Response to reviewer"s comment: Addressed. 3-17yo.
 8-12: Define "preserved cold-chain delivery". Response to reviewer"s comment: Addressed: "Specifically, the samples are stored in -80°C freezers at Rebiotix®, Minnesota, with nextday, on-site delivery in styrofoam-insulated boxes containing ice packs. Frozen enemas are removed from the boxes and stored in the clinic fridge (4oC) for up to 3 days."
 Enema product: volume and expected/required retention time not provided. This is very important in pediatric patients since capacity for enema retention is age dependent.
Response to reviewer"s comment: This was removed from the text as it could not be accurately controlled through the trial, due to varying ages, disease activity, and tolerance for the enema procedure. Standardizing retention times was not practical.
 3-29: The additional limitation of normal saline as technically (patients cannot blinded with NS compared to stool) and physiologically (auto-transplant is arguably a much better physiologic control/placebo) questionable control should be highlighted.
Response to reviewer"s comment:
The authors respectfully disagree with this comment. The existing literature on fecal transplant trials has not established that autologous transplants are a better study control than normal saline enemas.
(1) Physiologically, normal saline enemas are inert and less likely to confer impact on the host. Autologous enemas may confer a unique therapeutic potential. This has been highlighted in rCDI studies where autologous transplants were used as a control, and patients experienced significant response rates (62.5% of autologous FMT group experienced clinical cure for CDI vs. 90.9% with heterologous FMT; Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection. Ann Intern Med 2016;165:609-16).
(2) The normal saline enema is also not technically inferior to the intervention enema. Patients who received the control enema do not have a reference for the consistency or odour of the intervention enema. The control enema is given a brown color. When the control enema is excreted after the procedure, it is excreted along with the patients" recto-sigmoid fecal contents, conferring an odor and sediment. Finally, from our experience with patients in our trial, they would frequently incorrectly guess their treatment arm proving that the integrity of the placebo was retained.
 4-37: Of note, patient of reference 14 had colectomy within 1 year after the publication of the case (personal communication with authors). As stated in response to the reviewer's previous comment, normal saline enemas are not physiologically nor technically inferior to autologous enemas. These two RCTs had differences in their study designs that extended well beyond their choice of placebo control, alone. For reference, these differences have been clearly described in the commentary that accompanied the publication of these two articles in the same issue of Gastroenterology where Moayyedi et al, and Rossen et al"s RCTs were published. Grinspan AM, Kelly CR. Fecal Microbiota Transplantation for Ulcerative Colitis: Not Just Yet. Gastroenterology. 2015;149(1):15-8.)
 Use of the MRE has been removed from the protocol. This was originally described as an optional step in the protocol at the clinicians" discretion. No patients enrolled in the study thus far have actually had an actual end-of-study MRE performed, and the authors agree with the reviewers" comment that MRE findings have not been clearly established in the evaluation of (unprepped) colonic disease. . Response to reviewer"s comment: Statistical analysis was informed through the expertise of a clinical statistician affiliated with our research team. As recommended by our statistician, Fischer exact test has statistical superiority for smaller sample sizes (n<20), but as our sample size will exceed this (n=50), we were recommended to use Chi-square.
 9-6: Inaccurate statement: Significant worsening/flare of UC has been noted after FMT Response to reviewer"s comment: Addressed.
 9-17: By what method is VRE and MRSA screened? Response to reviewer"s comment: VRE is tested by enzyme immunoassay, and MRSA is screened by assessing growth on oxacillin-salt screening agar. We did not chose to state this in the protocol, as 19 other pathogens were listed in the same section and all were analyzed using standardized screens.
Major comments: 1. Eligibility criteria include "signs of disease activity" defined as a PUCAI score > 10. As a PUCAI score of < 10 already defines clinical remission, PUCAI score values for clinical activity have to be clearly separated from remission criteria. Following prior studies of pediatric UC and FMT (Kunde s. et al in 2013) or anti-TNF antibody therapy (Volonaki E et al. 2015) , PUCAI score for clinical activity should be at least 15. Modified the eligibility criteria to PUCAI ≥15. Although Volonaki never specifically set a number for activity in his/her protocol, PUCAI 15 coincided with the lowest PUCAI score of all patients at time of enrollment.
2. The enema product of the placebo group contains polyethylene glycol (PEG) preservative and saline. PEG has a laxative effect and applied twice weekly might increase PUCAI score. To ensure equal conditions in the placebo group, the same amount of PEG should also be used preparing the product of the FMT group. The protocol was modified to explain in greater detail the contents of the placebo, which do in fact include equal amounts of PEG. "25 patients will be randomized to receive normal saline enemas (control; saline/polyethylene glycol 3350) and 25 patients to receive a FMT enema (intervention; 50g/150ml, 107 microbes/mL of suspension in saline/polyethylene glycol 3350)".
Minor comments: 1. In the rationale section the authors refer to a 67-100% clinical response. In fact the cited paper of Kellermayer et al. demonstrated the prolongation of a symptom free interval due to FMT in patients after withdrawal of immunotherapy. These patients presented already with a Mayo score of 0 and 1 respectively even before the first FMT had been performed. "Protocols and response rates varied across each study, but lower gastrointestinal tract administration yielded clinical response rates in 67-100% of patients10,11." We do not agree with this being an inaccurate statement. In comparison to the other study mentioned in the same sentence used only 5 enemas. The response range was cleared stated (67-100%), based on varying protocols.
2. The cited case report of Vendaplas Y et al in 2015 deals with serial FMT infusion in a 18month old UC patient but donors were not anonymous as written in the protocol by Pai N and Popov J but age related relatives. This comment has been corrected, to clarify that donors were an age-matched niece and older brother donors.
Nylund L et al (BMC Microbiology 2013
) demonstrated an association of a diverse and adult-type microbiota in early childhood with eczema; this raises the question, if donors for the younger patients should be matched for age to prevent possible side effects. Several publications have now described age-specific differences in microbial composition, including differences in core microbial genera that vary beyond age 5yo to early adolescence. This literature would posit that age-matched microbiota should be prioritized for not only younger patients, but several broad age groups of childhood. While the authors agree that age-matched donors would be ideal, this was simply impractical through any private or public stool bank for our study. This would be a desirable future direction.
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